Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion

Katyayni Vinnakota1, Feng Hu, Min-Chi Ku

  • 1Corresponding Author: Prof Dr Helmut Kettenmann, PhD, Cellular Neurosciences, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, 13125 Berlin, Germany. kettenmann@mdc-berlin.de.

Neuro-Oncology
|September 10, 2013
PubMed
Abstract

Insights

Toll-like receptor 2 (TLR2) activation drives microglia to support glioma expansion by upregulating membrane type 1 matrix metalloprotease (MT1-MMP). Inhibiting TLR2 signaling in microglia may offer a novel therapeutic strategy for glioblastoma.

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cellular Biology

Background:

  • Glioblastomas are aggressive primary brain tumors.
  • Microglia accumulation correlates with glioblastoma malignancy and poor prognosis.
  • Microglia promote glioma expansion via MT1-MMP, dependent on MyD88 signaling.

Purpose of the Study:

  • Identify the specific Toll-like receptor (TLR) involved in microglia-mediated glioma expansion.
  • Investigate the role of TLR2 in regulating microglial MT1-MMP expression and promoting glioma growth.

Main Methods:

  • In vitro, ex vivo, and in vivo studies using GL261 glioma cells and TLR2 knockout mice.
  • Analysis of MT1-MMP expression in microglia and tumor tissues.
  • Assessment of tumor growth, survival rates, and microglial activation.

Main Results:

  • TLR2 knockout mice exhibited significantly smaller tumors, reduced MT1-MMP expression, and enhanced survival.
  • Tumor expansion in brain slices depended on parenchymal TLR2 and microglia.
  • TLR2 activation by glioma factors or ligands induced MT1-MMP in wild-type microglia but not in knockout microglia.
  • TLR1 and TLR6 were found to co-function with TLR2 as heterodimers.

Conclusions:

  • TLR2 is the primary TLR controlling microglial MT1-MMP expression and promoting glioma expansion.
  • Activation of TLR2, potentially with TLR1 and/or TLR6, induces a glioma-supportive phenotype in microglia.
  • Targeting TLR2 represents a potential therapeutic avenue for glioblastoma treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...